Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reproductive Health Cmte. Line-Up Set; First Priority Will Be WHI Results

Executive Summary

The new roster of FDA's Reproductive Health Drugs Advisory Committee includes two members who have conducted research or educational activities on hormone replacement therapy sponsored by Wyeth
Advertisement

Related Content

FDA Advisory Cmte. Members Should Be Vetted For Opinions, GAO Says
FDA Advisory Cmte. Members Should Be Vetted For Opinions, GAO Says
Ortho Oral Contraceptives May Add Folic Acid, New Patent Life
Ortho Oral Contraceptives May Add Folic Acid, New Patent Life
FDA Reproductive Health Drugs Cmte. returns
FDA DTC Stance Is “Ideological,” Not Science-Based, Rep. Waxman Says
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
FDA Women’s Health Initiative Advisory Committee Meeting Postponed
FDA Women’s Health Initiative Advisory Committee Meeting Postponed
FDA Reproductive Cmte. Membership Reflects “Broken Process” – Crawford
Advertisement
UsernamePublicRestriction

Register

PS041047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel